Skip to main content
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. — Investor Relations & Filings

Ticker · VIR ISIN · US92764N1028 US Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2026-05-28 Declaration of Voting R…
Country US United States of America
Listing US VIR

About Vir Biotechnology, Inc.

https://www.vir.bio/

Vir Biotechnology, Inc. is a clinical-stage immunology company that leverages the immune system to treat and prevent serious infectious diseases and other conditions. The company's pipeline is built on two primary technology platforms: a next-generation antibody platform for identifying and optimizing therapeutic candidates, and the PRO-XTEN® protease-releasable masking technology for applications in oncology. Vir's main therapeutic area is infectious diseases, featuring a leading program for chronic hepatitis delta, and is complemented by strategic programs in oncology. The company has demonstrated its capabilities by developing antibody-based medicines for significant health challenges, including COVID-19 and Ebola.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a Form 8-K “Current Report” covering two SEC Item disclosures: 5.02 (director departure and appointment) and 5.07 (submission of matters to a vote of security holders). It provides official vote results for each proposal at the Annual Meeting. The presence of detailed voting tallies makes this a Declaration of Voting Results filing, matching code DVA.
2026-05-28 English
DEF 14A - Vir Biotechnology, Inc. (0001706431) (Filer)
Proxy Solicitation & Information Statement
2026-04-16 English
8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 7, 2026, reporting the departure of a senior executive, Mark Eisner, MD, MPH, who is stepping down as Executive Vice President and Chief Medical Officer. The key section is Item 5.02, which pertains to changes in directors or certain officers. There is no financial data or report attached, and the document is relatively short (2855 characters). This matches the description of Board/Management Information filings, which announce changes in the company's board or senior management. Therefore, the appropriate classification is MANG (Board/Management Information).
2026-04-10 English
SCHEDULE 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)
Major Shareholding Notification
2026-03-27 English
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
Director's Dealing
2026-03-23 English
144 - Vir Biotechnology, Inc. (0001706431) (Subject)
Regulatory Filings
2026-03-23 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.